RxDoctor Payments Data

Timothy Burke, DO

Internal Medicine · Jermyn, PANPI 1609188945

Payments from drug & device makers

$339in general payments, 2019–2025

Across 19 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$56
  • Indivior Inc.$41
  • Novo Nordisk$40
  • Abbott$39
  • Dexcom, Inc.$33
  • AbbVie$29
  • plus $101 from 6 others

What the payments were for

  • Food & beverage$339100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$339 in reported general payments places this provider in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$16,324
Medicare patients
131
Services billed
295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban99$76,520
OzempicSemaglutide48$54,548
JardianceEmpagliflozin57$38,892
FarxigaDapagliflozin Propanediol24$23,850
TradjentaLinagliptin43$23,526
EntrestoSacubitril/Valsartan27$18,404
MounjaroTirzepatide15$16,010
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$15,849
JanuviaSitagliptin Phosphate17$14,016
XareltoRivaroxaban17$13,505
LinzessLinaclotide14$10,367
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$9,530
ShingrixVaricella-Zoster Ge/As01b/Pf38$8,366
JanumetSitagliptin Phos/Metformin Hcl14$8,009
AbrysvoRsv Vacc, Pref A And Pref B/Pf23$7,316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$56$83,835122 claims
Novo NordiskOzempic$40$54,54848 claims
GSKTrelegy Ellipta, Shingrix$15$24,21560 claims
MerckJanuvia, Janumet$16$22,02531 claims
AbbVieLinzess, Creon, Synthroid$29$16,18648 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Jermyn

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →